Previous presentation: This study was featured as “News of the Day” press briefing on June 2, 2017, and presented at the 2017 ASCO Annual Meeting; June 2–5, 2017; Chicago, Illinois.
Author contributions: Study concept and design: Sesso, Einhorn, Travis. Financial and administrative support: Travis. Provision of study materials or patients: Fung, Feldman, Hamilton, Vaughn, Beard, Einhorn, Travis. Collection and assembly of data: Abu Zaid, Feldman, Cook, Althouse, Travis. Data analysis and interpretation: All authors. Drafting and final approval of manuscript: All authors.
Disclosures: The authors have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: This study was funded by the National Cancer Institute (R01 CA157823, to L.B.T.) and the National Institute of General Medical Sciences (U19 GM061390). The NCI had no role in the design of the study; the collection, analysis, or interpretation of data; the writing of the manuscript; or the decision to submit the manuscript for publication.
Nigam MAschebrook-Kilfoy BShikanov S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015;33:623–631.
Verdecchia AFrancisci SBrenner H. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784–796.
Capocaccia RGatta GDal Maso L. Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data. Ann Oncol 2015;26:1263–1268.
Travis LBBeard CAllan JM. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114–1130.
Araujo ABEsche GRKupelian V. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241–4247.
Kaufman JMVermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833–876.
Harman SMMetter EJTobin JD. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724–731.
Feldman HALongcope CDerby CA. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–598.
Isidori AMGiannetta EGreco EA. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280–293.
Hildreth KLBarry DWMoreau KL. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013;98:1891–1900.
Ohlsson CWallaschofski HLunetta KL. Genetic determinants of serum testosterone concentrations in men. PLoS Genet 2011;7:e1002313.
De Groot LJChrousos GDungan K. Testicular cancer pathogenesis, diagnosis and endocrine aspects. In: Feingold KRAnawalt BBoyce A eds. Endotext [internet]. South Dartmouth, MA: MDText.com, Inc.; 2000.
Skakkebæk NERajpert-De Meyts EMain KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:972–978.
Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006;12:303–323.
Fung CSesso HDWilliams AM. Multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J Clin Oncol 2017;35:1211–1222.
Kerns SLFung CMonahan PO. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol 2018;36:1505–1512.
Zaid MAGathirua-Mwangi WGFung C. Clinical and genetic risk factors for adverse metabolic outcomes in North American testicular cancer survivors. J Natl Compr Canc Netw 2018;16:257–265.
Taylor HLJacobs DR JrSchucker B. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741–755.
Chasan-Taber SRimm EBStampfer MJ. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81–86.
Ainsworth BEHaskell WLHerrmann SD. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc 2011;43:1575–1581.
Desroches BKohn TPWelliver C. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol 2016;5:207–212.
Wheeler HEGamazon ERFrisina R. Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res 2017;23:3325–3333.
Howie BFuchsberger CStephens M. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955–959.
Barrett-Connor EKhaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78:539–545.
Khaw KTDowsett MFolkerd E. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694–2701.
- Search Google Scholar
- Export Citation
)| false . , Khaw KT , Dowsett M , Folkerd E Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. 2007; 116: 2694– 2701. 18040028 10.1161/CIRCULATIONAHA.107.719005
Kupelian VHayes FJLink CL. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008;93:3403–3410.
Haring RVölzke HSteveling A. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494–1501.
Li CFord ESLi B. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 2010;33:1618–1624.
Nuver JSmit AJWolffenbuttel BH. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718–3725.
Wethal TKjekshus JRøislien J. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007;1:8–16.
de Haas ECAltena RBoezen HM. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013;24:749–755.
Willemse PMBurggraaf JHamdy NA. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors [published correction appears in Br J Cancer 2013;109:295–296]. Br J Cancer 2013;109:60–67.
- Search Google Scholar
- Export Citation
)| false . , Willemse PM , Burggraaf J , Hamdy NA Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors [published correction appears in Br J Cancer 2013;109:295–296]. 2013; 109: 60– 67. 10.1038/bjc.2013.226
Haugnes HSAass NFosså SD. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18:241–248.
Fung CFossa SDMilano MT. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 2015;33:3105–3115.
Haugnes HSWethal TAass N. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649–4657.
Huddart RANorman AShahidi M. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–1523.
Meinardi MTGietema JAvan der Graaf WT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725–1732.
van den Belt-Dusebout AWde Wit RGietema JA. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370–4378.
Dolan MEEl Charif OWheeler HE. Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 2017;23:5757–5768.
Gerl AMühlbayer DHansmann G. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001;91:1297–1303.
Isaksson SBogefors KStåhl O. High risk of hypogonadism in young male cancer survivors. Clin Endocrinol (Oxf) 2018;88:432–441.
Ferlin ABogatcheva NVGianesello L. Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. Mol Hum Reprod 2006;12:401–406.
Xing JSBai ZM. Is testicular dysgenesis syndrome a genetic, endocrine, or environmental disease, or an unexplained reproductive disorder? Life Sci 2018;194:120–129.
Foresta CFerlin A. Role of INSL3 and LGR8 in cryptorchidism and testicular functions. Reprod Biomed Online 2004;9:294–298.
Basaria SCoviello ADTravison TG. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109–122.
Srinivas-Shankar URoberts SAConnolly MJ. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010;95:639–650.
- Search Google Scholar
- Export Citation
)| false . , Srinivas-Shankar U , Roberts SA , Connolly MJ Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. 2010; 95: 639– 650. 10.1210/jc.2009-1251
Budoff MJEllenberg SSLewis CE. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 2017;317:708–716.
Bhasin SCunningham GRHayes FJ. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
Postma TJAaronson NKHeimans JJ. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135–1139.
Oldenburg JFosså SDDahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res 2006;15:791–800.
Ventry IMWeinstein BE. The hearing handicap inventory for the elderly: a new tool. Ear Hear 1982;3:128–134.